Article Text
Abstract
Objectives To estimate the age and type-specific distribution of low-risk (LR) human papillomavirus (HPV) types in cervical samples from women in the general population and to assess the distribution of LR-HPV without the coexistence of high-risk HPV types in different cytology and histology categories.
Methods In a cross-sectional study, liquid-based cytology samples (SurePath) were collected over a 3-year period. The samples were HPV tested by Hybrid Capture II (HC2; Digene) and genotyped using a PCR-based assay (INNO-LiPAv2; Innogenetics Inc.). A total of 40 382 women (14–95 years of age) were included in the study. By linkage with the nationwide Pathology Data Bank, the HPV test results were directly linked to cytological diagnoses made from the same samples and to subsequent histology results.
Results Overall, 2790 women (6.9%) tested positive for LR-HPV types, with HPV6 and HPV70 being the most frequent types detected, whereas HPV11 was uncommon. The highest prevalence was observed in the youngest age group (≤19 years). The LR-HPV prevalence was 6.3% in women with normal cytology, 33.1% in atypical squamous cells of undetermined significance (ASCUS), 19.6% in low-grade squamous intraepithelial lesion and 12.7% in those with high-grade squamous intraepithelial lesion. When considering women with LR-HPV alone, the prevalence was 2.0% (normal cytology), 11.3% (ASCUS), 2.6% (low-grade squamous intraepithelial lesion) and 0.7% in women with high-grade squamous intraepithelial lesion, respectively. A similar pattern was observed in relation to the histological diagnoses with the majority of LR-HPV infections detected in CIN1 lesions (24.7%).
Conclusions LR-HPV types alone are relatively common in ASCUS, whereas LR-HPV types without coexisting high-risk HPV types are virtually never detected in severe cervical lesions.
- Human papillomavirus
- prevalence of low-risk types
- association with cervical lesions
Statistics from Altmetric.com
Footnotes
-
Funding The study was funded through an institutional grant from Sanofi Pasteur MSD (Lyon, France) and from the Danish Cancer Society. Furthermore, the study was supported by MERMAID (Mermaid 2 project). The funders had no role in the conduction or interpretation of the study. The authors take full responsibility for the content of this contribution.
-
Competing interests None.
-
Ethics approval Ethics approval was provided by the Danish Data Protection Agency and the Danish Scientific Ethical Committee.
-
Provenance and peer review Not commissioned; externally peer reviewed.